68Ga-FAP-CHX PET/CT : Dosimetry and Preliminary Clinical Translational Studies

Launched by FIRST AFFILIATED HOSPITAL OF FUJIAN MEDICAL UNIVERSITY · Aug 17, 2022

Keywords

ClinConnect Summary

This clinical trial, called 68Ga-FAP-CHX PET/CT, is exploring a new imaging agent called 68Ga-FAP-CHX, which may help doctors see and understand various types of cancer better. The researchers want to find out how safe this imaging agent is, how it spreads in the body, and how much radiation it delivers. They will compare the results of this new agent with other imaging methods to see which is more effective for diagnosing tumors.

To participate in this study, you need to be between 18 and 75 years old and have a solid tumor that hasn’t been treated with surgery yet. You will also need to give your consent to join the study. If you’re pregnant or unable to provide consent, you won’t be eligible. If you choose to participate, you can expect to undergo some imaging tests and contribute to important research that could improve cancer diagnosis in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 years \< Age \< 75 years
• • Various solid tumors with available histopathological findings, and have not been treated surgically.
• • Signed informed consent.
• Exclusion Criteria:
• • patients with pregnancy
• • the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.